Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Alzheimers Dement (N Y) ; 8(1): e12274, 2022.
Article in English | MEDLINE | ID: mdl-35415206

ABSTRACT

Introduction: The neuronal mechanism driving Alzheimer's disease (AD) is incompletely understood. Methods: Immunohistochemistry, pharmacology, biochemistry, and behavioral testing are employed in two pathological contexts-AD and a transgenic mouse model-to investigate T14, a 14mer peptide, as a key signaling molecule in the neuropathology. Results: T14 increases in AD brains as the disease progresses and is conspicuous in 5XFAD mice, where its immunoreactivity corresponds to that seen in AD: neurons immunoreactive for T14 in proximity to T14-immunoreactive plaques. NBP14 is a cyclized version of T14, which dose-dependently displaces binding of its linear counterpart to alpha-7 nicotinic receptors in AD brains. In 5XFAD mice, intranasal NBP14 for 14 weeks decreases brain amyloid and restores novel object recognition to that in wild-types. Discussion: These findings indicate that the T14 system, for which the signaling pathway is described here, contributes to the neuropathological process and that NBP14 warrants consideration for its therapeutic potential.

2.
Bioorg Med Chem ; 21(21): 6264-73, 2013 Nov 01.
Article in English | MEDLINE | ID: mdl-24075145

ABSTRACT

The last two decades have provided a large weight of preclinical data implicating the neurokinin-1 receptor (NK1) and its cognate ligand substance P (SP) in a broad range of both central and peripheral disease conditions. However, to date, only the NK1 receptor antagonist aprepitant has been approved as a therapeutic and this is to prevent chemotherapy-induced nausea & vomiting (CINV). The belief remained that the full therapeutic potential of NK1 receptor antagonists had yet to be realized; therefore clinical evidence that NK1 receptor antagonists may be effective in major depression disorder, resulted in a significant further investment in discovering novel CNS penetrant druggable NK1 receptor antagonists to address this condition. At GlaxoSmithKline after the discovery of casopitant, that went on to demonstrate efficacy as a novel antidepressant in the clinic, additional novel analogues of this NK1 receptor antagonist were designed to further enhance its drug developability characteristics. Herein, we therefore describe the discovery process and the vivo pharmacological and pharmacokinetic profile of the new NK1 receptor antagonist 3a (also called orvepitant), selected as clinical candidate and further progressed into clinical studies for major depressive disorder. Moreover, molecular modeling studies enabled us to improve the pharmacophore model of the NK1 receptor antagonists with the identification of a region able to accommodate a variety of heterocycle moieties.


Subject(s)
Antidepressive Agents/chemistry , Neurokinin-1 Receptor Antagonists/chemistry , Receptors, Neurokinin-1/chemistry , Animals , Antidepressive Agents/chemical synthesis , Antidepressive Agents/pharmacokinetics , Behavior, Animal/drug effects , Bridged Bicyclo Compounds, Heterocyclic/chemical synthesis , Bridged Bicyclo Compounds, Heterocyclic/chemistry , Bridged Bicyclo Compounds, Heterocyclic/pharmacokinetics , CHO Cells , Cricetinae , Cricetulus , Dogs , Female , Gerbillinae , Half-Life , Humans , Male , Models, Molecular , Molecular Conformation , Neurokinin-1 Receptor Antagonists/chemical synthesis , Neurokinin-1 Receptor Antagonists/pharmacokinetics , Piperazines/chemistry , Piperidines/chemical synthesis , Piperidines/chemistry , Piperidines/pharmacokinetics , Protein Binding , Rats , Receptors, Neurokinin-1/genetics , Receptors, Neurokinin-1/metabolism
3.
J Med Chem ; 54(4): 1071-9, 2011 Feb 24.
Article in English | MEDLINE | ID: mdl-21229983

ABSTRACT

A large body of compelling preclinical evidence supports the clinical use of neurokinin (NK) receptor antagonists in a plethora of CNS and non-CNS therapeutic areas. The significant investment made in this area over the past 2 decades culminated with the observation that NK(1) receptor antagonists elicited clinical efficacy in major depression disorders. In addition, aprepitant (Merck) was launched as a new drug able to prevent chemotherapy-induced nausea and vomiting (CINV). After the discovery by GlaxoSmithKline of vestipitant, a wide drug discovery program was launched aimed at identifying additional clinical candidates. New compounds were designed to maximize affinity at the NK(1) receptor binding site while retaining suitable physicochemical characteristics to ensure excellent pharmacokinetic and pharmacodynamic properties in vivo. Herein we describe the discovery process of a new NK(1) receptor antagonist (casopitant) selected as clinical candidate and progressed into clinical studies to treat major depression disorders.


Subject(s)
Brain/drug effects , Brain/metabolism , Depressive Disorder/drug therapy , Neurokinin-1 Receptor Antagonists , Piperazines/chemical synthesis , Piperazines/pharmacology , Piperidines/chemical synthesis , Piperidines/pharmacology , Animals , Behavior, Animal/drug effects , CHO Cells , Cricetinae , Cricetulus , Depressive Disorder/metabolism , Drug Discovery , Gerbillinae , Half-Life , Humans , Magnetic Resonance Spectroscopy , Piperazines/chemistry , Piperazines/pharmacokinetics , Piperidines/chemistry , Piperidines/pharmacokinetics , Regression Analysis , Spectrometry, Mass, Electrospray Ionization , Spectrophotometry, Infrared , Stereoisomerism
4.
J Med Chem ; 52(10): 3238-47, 2009 May 28.
Article in English | MEDLINE | ID: mdl-19388677

ABSTRACT

In an effort to discover novel druglike NK(1) receptor antagonists a new series of suitably substituted C-phenylpiperazine derivatives was identified by an appropriate chemical exploration of related N-phenylpiperazine analogues, with the specific aim to maximize their in vitro affinity and optimize in parallel their pharmacokinetic profile. Among the compounds synthesized, 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) was identified as one of the most in vitro potent and selective NK(1) receptor antagonists ever discovered, showing appropriate pharmacokinetic properties and in vivo activity. On the basis of its preclinical profile, this compound was selected as a drug candidate.


Subject(s)
Neurokinin-1 Receptor Antagonists , Piperazines/chemistry , Piperidines/pharmacology , Administration, Oral , Animals , CHO Cells , Cricetinae , Cricetulus , Drug Discovery , Drug Evaluation, Preclinical , Fluorobenzenes , Gerbillinae , Pharmacokinetics , Piperazines/pharmacology , Piperidines/pharmacokinetics , Structure-Activity Relationship
5.
Addict Biol ; 12(1): 22-9, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17407494

ABSTRACT

Ghrelin is a brain-gut peptide with growth hormone-releasing and appetite-inducing activities. A growing body of evidence suggests that ghrelin may affect the central reward system and modulate the activity of the mesolimbic system. Recent clinical studies also showed a significant positive correlation between plasma ghrelin levels and craving in alcoholics. Accordingly, the present study investigated the potential role of serum ghrelin levels in the reinstatement of cocaine-seeking behaviour triggered by cocaine-associated cues. In addition, serum corticosterone levels were determined in the light of evidence suggesting that corticosterone plays a modulatory role in cocaine-seeking behaviour. Male Lister Hooded rats under a restricted diet regime were first trained to intravenously self-administer cocaine under a fixed ratio-1 schedule of reinforcement. Conditioned stimuli (CS: tone and cue-light on for 5 seconds) were presented contingently with cocaine delivery. Once a stable baseline of cocaine self-administration was observed, lever presses were extinguished to less than 30% of baseline rates by removing both cocaine and CS. Reinstatement of responding was then induced by re-exposure to cocaine-associated CS. Blood samples for the enzyme immunoassay determination of serum ghrelin and the radioimmunoassay determination of serum corticosterone levels were collected 30 minutes before the beginning of reinstatement sessions. Rats significantly reinstated their responding when exposed to CS. A positive and significant correlation was observed between ghrelin levels (r = 0.64; P < 0.05), but not corticosterone (r = 0.37; NS), and the increased active lever presses only in animals exposed to CS. These findings suggest a potential role of ghrelin in the modulation of cue-triggered reinstatement of cocaine-seeking behaviour.


Subject(s)
Cocaine-Related Disorders/physiopathology , Conditioning, Classical/physiology , Motivation , Peptide Hormones/blood , Animals , Corticosterone/blood , Cues , Ghrelin , Injections, Intravenous , Male , Rats , Reinforcement Schedule , Self Administration , Statistics as Topic
6.
Neurosci Lett ; 345(2): 73-6, 2003 Jul 17.
Article in English | MEDLINE | ID: mdl-12821174

ABSTRACT

We tested fluoxetine, bupropion and GR 205171, a selective neurokinin-1 receptor antagonist on forced swimming test (FST) response and on levels of monoamines in frontal cortex of CD1 mice by microdialysis techniques. All drugs decreased immobility time. Fluoxetine augmented all monoamines, bupropion enhanced catecholamines, and GR 205171 was totally ineffective. Results suggest that FST response may not be related to levels of monoamines in the mouse frontal cortex.


Subject(s)
Antidepressive Agents/pharmacology , Biogenic Monoamines/metabolism , Neurokinin-1 Receptor Antagonists , Piperidines/pharmacology , Prefrontal Cortex/drug effects , Swimming , Tetrazoles/pharmacology , Animals , Behavior, Animal/drug effects , Bupropion/pharmacology , Extracellular Space/drug effects , Extracellular Space/metabolism , Fluoxetine/pharmacology , Immobilization , Mice , Mice, Inbred Strains , Prefrontal Cortex/metabolism , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...